Small caps are opening the week amid softer commodities and renewed tech volatility offshore, but today’s news flow remains active. Several juniors have delivered material updates across critical minerals, high-grade drilling, operational progress and clinical development.
Resolution Minerals
Resolution Minerals Ltd (ASX:RML, OTC:RLMLF) has appointed Dr Adam Roper as chief metallurgist – critical metals extraction, strengthening its downstream strategy for antimony, tungsten and gold.
Dr Roper — a specialist in antimony geochemistry with extensive flowsheet and piloting experience at ANSTO Minerals and in advanced chemical processing — will lead the company’s push to establish US-aligned critical minerals processing capability.
Far East Gold
Far East Gold Ltd (ASX:FEG) has returned further high-grade gold assays from the Sua prospect in Papua, with holes KSD025 and KSD026 confirming and extending historical mineralisation. Intervals included grades up to 51 g/t Au, multiple stacked veins, and a deeper high-grade zone not captured in earlier drilling.
The mineralised system remains open down-dip and along strike.
Lindian Resources
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) hosted senior US government representatives at the Kangankunde Rare Earths Project in Malawi, reinforcing the project’s relevance to global critical mineral supply chains. Discussions focused on development progress and Kangankunde’s potential role in future US-aligned rare-earth pathways, with first production targeted for 2026.
Tamboran Resources
Tamboran Resources Corporation (ASX:TBN, NYSE:TBN, OTC:TBNRL) has completed stimulation of the SS-6H well at Shenandoah South, delivering its largest Beetaloo Basin program with 58 stages across a 10,009-foot lateral.
Around 86% of the horizontal section is expected to contribute to flow, with a 30-day test scheduled for 1Q 2026 as pipeline and compression facility construction continues.
Orthocell
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has submitted its EU and UK regulatory application for Remplir™, seeking CE and UKCA certification for entry into the US$750 million nerve-repair market.
The submission is supported by an 81.1% success rate from its Real-World Evidence study, with approval expected in 3Q CY26.
Prescient Therapeutics
Prescient Therapeutics Ltd (ASX:PTX) has secured European authorisation to commence its PTX-100 Phase 2a trial in relapsed/refractory CTCL, enabling activation of Italian trial sites. The company says the approval represents a key step in expanding its global clinical footprint for PTX-100.